Other MS patients, a minority, have a form of the disease that features gradually increasing progressive disability from onset—so-called primary progressive MS (PPMS). While effective disease ...

This exploratory study assessed the safety and clinical benefit of masitinib in the treatment of primary progressive MS (PPMS) or relapse-free secondary progressive MS (rfSPMS). Methods ...

National Multiple Sclerosis Society: "FDA Approves Ocrevus™ (ocrelizumab) for People with Primary Progressive MS or Relapsing MS -- First Disease-Modifying Therapy for Primary Progressive MS ...

Sanofi is also running a fourth phase 3 trial called PERSEUS in patients with primary progressive MS (PPMS). Earlier this year, it abandoned its development in another neuromuscular disorder ...

clinically isolated syndrome relapsing-remitting MS secondary progressive MS primary progressive MS There’s no one set timeline or course of MS, but knowing the type can help you understand and ...

Clinically isolated syndrome Relapsing remitting MS Secondary progressive MS Primary progressive MS You get ocrelizumab through an infusion into your vein in a doctor’s office or clinic.

Higher blood levels of bile acids, molecules that aid fat absorption in the gut, are linked to slower MS progression, per ...

and primary progressive multiple sclerosis (PPMS). An electronic version of the Symbol-Digit Modalities Test could enable people with multiple sclerosis (MS) to perform frequent remote cognitive ...

A new drug for people who have one of the worst forms of multiple sclerosis aims to make treatment much easier for patients. Ocrevus is a medicine commonly used to treat primary progressive MS ...

After a series of tests and a lumbar puncture, Mr Foniadakis was told he had “one of the worst kinds” of multiple sclerosis — ...

In its first draft guidance, NICE said that Ocrevus (ocrelizumab) is not cost-effective in primary progressive multiple sclerosis (PPMS). The cost-effectiveness body noted clinical trial evidence ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...